AU2020284742B2 - Novel compounds for inhibition of Janus Kinase 1 - Google Patents

Novel compounds for inhibition of Janus Kinase 1

Info

Publication number
AU2020284742B2
AU2020284742B2 AU2020284742A AU2020284742A AU2020284742B2 AU 2020284742 B2 AU2020284742 B2 AU 2020284742B2 AU 2020284742 A AU2020284742 A AU 2020284742A AU 2020284742 A AU2020284742 A AU 2020284742A AU 2020284742 B2 AU2020284742 B2 AU 2020284742B2
Authority
AU
Australia
Prior art keywords
pyridin
imidazo
pyrazol
trifluoro
pyridine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2020284742A
Other languages
English (en)
Other versions
AU2020284742A1 (en
Inventor
Sazid ALI
Mahadev BANDGAR
Srinivasa Reddy Bapuram
Amol Pandurang Gunjal
Anil Kumar
Rakesh Iswar PATIL
Himanshu RAI
Santosh Kumar Rai
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mankind Pharma Ltd
Original Assignee
Mankind Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mankind Pharma Ltd filed Critical Mankind Pharma Ltd
Publication of AU2020284742A1 publication Critical patent/AU2020284742A1/en
Application granted granted Critical
Publication of AU2020284742B2 publication Critical patent/AU2020284742B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2020284742A 2019-05-28 2020-05-26 Novel compounds for inhibition of Janus Kinase 1 Active AU2020284742B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201911021098 2019-05-28
IN201911021098 2019-05-28
PCT/IN2020/050471 WO2020240586A1 (en) 2019-05-28 2020-05-26 Novel compounds for inhibition of janus kinase 1

Publications (2)

Publication Number Publication Date
AU2020284742A1 AU2020284742A1 (en) 2022-02-03
AU2020284742B2 true AU2020284742B2 (en) 2026-03-05

Family

ID=73553608

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2020284742A Active AU2020284742B2 (en) 2019-05-28 2020-05-26 Novel compounds for inhibition of Janus Kinase 1

Country Status (11)

Country Link
US (1) US12516056B2 (https=)
EP (1) EP3976612A4 (https=)
JP (1) JP7592029B2 (https=)
CN (1) CN114174294B (https=)
AU (1) AU2020284742B2 (https=)
BR (1) BR112021023635A2 (https=)
CA (1) CA3141571A1 (https=)
MX (1) MX2021014361A (https=)
TW (1) TWI839524B (https=)
WO (1) WO2020240586A1 (https=)
ZA (1) ZA202109183B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023526521A (ja) * 2020-05-21 2023-06-21 ステムシナジー セラピューティクス， インク． Ｎｏｔｃｈ阻害剤及びそれらの使用
WO2022166796A1 (zh) * 2021-02-05 2022-08-11 上海齐鲁制药研究中心有限公司 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途
PE20250019A1 (es) * 2021-05-06 2025-01-07 Exscientia Ai Ltd MODULADORES DE PKC-theta
WO2022234298A1 (en) * 2021-05-06 2022-11-10 Exscientia Ai Limited Pkc-theta modulators
EP4452944A1 (en) * 2021-12-22 2024-10-30 Icagen, LLC Cyclopropyl compounds
CN117050074B (zh) * 2022-05-05 2025-08-12 中国药科大学 一类吡啶联咪唑并吡啶化合物及其制备方法与用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189617A1 (en) * 2005-02-18 2006-08-24 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
WO2007040438A2 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
CN106146504A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
WO2018035080A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof
US20180289680A1 (en) * 2015-12-11 2018-10-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5002851B2 (ja) * 2005-01-20 2012-08-15 独立行政法人理化学研究所 イミダゾピリジン誘導体
SG10202003901UA (en) * 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
EP2244711A4 (en) * 2008-02-04 2011-08-24 Cytokinetics Inc CERTAIN CHEMICAL ENTITIES, COMPOSITIONS AND METHODS
WO2010036316A1 (en) 2008-09-24 2010-04-01 Yangbo Feng Urea and carbamate compounds and analogs as kinase inhibitors
FI124118B (fi) * 2011-06-13 2014-03-31 Reijo Uolevi Hautalahti Aurinkoenergian avulla sähköä ja lämpöä tuottava voimala
KR20130076046A (ko) * 2011-12-28 2013-07-08 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
ES2567552T3 (es) * 2012-01-30 2016-04-25 Cephalon, Inc. Imidazo [4,5-b] derivados de piridina como los moduladores ALK y JAK para el tratamiento de trastornos proliferativos
CN104140426B (zh) * 2013-05-07 2017-02-01 上海汇伦生命科技有限公司 嘧啶并咪唑类化合物、其药物组合物及其制备方法和用途
US10253023B2 (en) 2014-10-06 2019-04-09 Merck Patent Gmbh Heteroaryl compounds as BTK inhibitors and uses thereof
CN105837572B (zh) 2015-02-02 2019-04-19 四川大学 N-取代苯基酰胺衍生物及其制备方法和用途
GB201717260D0 (en) 2017-10-20 2017-12-06 Galapagos Nv Novel compounds and pharma ceutical compositions thereof for the treatment of inflammatory disorders
CN113508114B (zh) * 2019-02-27 2024-03-26 四川科伦博泰生物医药股份有限公司 以氮杂环丁烷衍生物为活性成分的口服药物组合物、其制备方法及用途

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060189617A1 (en) * 2005-02-18 2006-08-24 Wyeth Imidazo[4,5-b]pyridine antagonists of gonadotropin releasing hormone receptor
WO2007040438A2 (en) * 2005-10-03 2007-04-12 Astrazeneca Ab Novel imidazo [4,5 -b] pyridine derivatives as inhibitors of glycogen synthase kinase 3 for use in the treatment of dementia and neurodegenerative disorders
WO2010003133A2 (en) * 2008-07-03 2010-01-07 Exelixis Inc. Cdk modulators
CN106146504A (zh) * 2015-04-17 2016-11-23 上海汇伦生命科技有限公司 一种杂环并咪唑类化合物、其药物组合物及其制备方法和用途
US20180289680A1 (en) * 2015-12-11 2018-10-11 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Azetidine derivative, preparation method therefor, and use thereof
WO2018035080A1 (en) * 2016-08-16 2018-02-22 Merck Patent Gmbh 2-oxo-imidazopyridines as reversible btk inhibitors and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2012, vol. 22, no. 4, pages 1611 - 1614. *
CAS Registry Number 2177263-65-7; STN Entry Date 20 February 2018 *
CHEMISTRY & BIODIVERSITY, 2012, vol. 9, no. 11, pages 2442 - 2452. *
JOURNAL OF MEDICINAL CHEMISTRY, 2019, vol. 62, no. 5, pages 2447 - 2465. *

Also Published As

Publication number Publication date
TW202110838A (zh) 2021-03-16
JP7592029B2 (ja) 2024-11-29
CA3141571A1 (en) 2020-12-03
ZA202109183B (en) 2022-08-31
EP3976612A4 (en) 2023-04-26
US20220235046A1 (en) 2022-07-28
CN114174294A (zh) 2022-03-11
EP3976612A1 (en) 2022-04-06
CN114174294B (zh) 2024-10-25
MX2021014361A (es) 2022-04-06
US12516056B2 (en) 2026-01-06
BR112021023635A2 (pt) 2022-02-01
JP2022534510A (ja) 2022-08-01
AU2020284742A1 (en) 2022-02-03
WO2020240586A1 (en) 2020-12-03
TWI839524B (zh) 2024-04-21

Similar Documents

Publication Publication Date Title
AU2020284742B2 (en) Novel compounds for inhibition of Janus Kinase 1
AU2022263410B2 (en) Carboxy-benzimidazole glp-1r modulating compounds
JP7001682B2 (ja) 置換１Ｈ－イミダゾ［４，５－ｂ］ピリジン－２（３Ｈ）－オン及びＧＬＵＮ２Ｂ受容体調節因子としてのそれらの使用
AU2016231289B2 (en) Benzazepine dicarboxamide compounds
US11524968B2 (en) Heterocyclic compound as a protein kinase inhibitor
AU2014400628B2 (en) Aminopyridazinone compounds as protein kinase inhibitors
KR100980163B1 (ko) 데아자퓨린 및 이의 용도
CN100376571C (zh) 6-取代的吡啶并嘧啶类化合物
US20100216798A1 (en) Fused heterocycles as lck inhibitors
AU2019416589A1 (en) Heterocyclic compound intermediate, preparation method therefor and application thereof
KR20180006334A (ko) 신규한 4-아미노피라졸로[3,4-d]피리미디닐아자바이사이클로 유도체 및 이를 포함하는 약학 조성물
JP7709466B2 (ja) Ｉｌ－１７ａモジュレーター
US20050090507A1 (en) Pyrazolopyridazine derivatves
RS50476B (sr) Derivati pirazolo (4,3-d) pirimidina
TW202210466A (zh) 治療性化合物
AU2009327127A1 (en) Cyclic pyrimidin-4-carboxamides as CCR2 receptor antagonists for treatment of inflammation, asthma and COPD
AU2021256157B2 (en) Tricyclic compounds as EGFR inhibitors
CA2666375A1 (en) 3-aminoimidazo[1,2-a]pyridine derivatives having an sglt1- and sglt2- inhibiting action for the treatment of type 1 and type 2 diabetes
ZA200404168B (en) Ä1,2,4Ü-Triazole bicyclic adenosing A2a receptor antagonists.
KR20230157432A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체
US9115149B2 (en) Heterocyclic compounds as inhibitors of fatty acid biosysnthesis for bacterial infections
TW202302583A (zh) Ｔｙｋ２抑制劑及其用途
CN116262750A (zh) 一种芳杂环类化合物及其制备方法和用途
AU2020403681B2 (en) Compound and composition as pdgf receptor kinase inhibitor
KR20230157431A (ko) 야누스 키나아제 억제제로서 헤테로사이클릭 유도체